The Catalyst

Most Recent Posts

06.22.11 | By Kate Connors

This week, the Kaiser Family Foundation released the results of a survey seeking to capture the public's opinions about HIV/AIDS.

06.21.11 | By Lorraine Egan

Earlier today, the Damon Runyon Cancer Research Foundation launched 'Accelerating Cancer Cures,' a new initiative that brings together PhRMA, some of the industry's leading companies, and partners in academia to address the critical shortage of new young physician-scientists choosing careers in research, while also advancing a translational research model that will play a key role in discovering tomorrow's cancer cures.

06.21.11 | By Kate Connors

Tomorrow, PhRMA and the U.S. Department of Commerce will convene a roundtable discussion on export opportunities for biopharmaceutical research companies, with a particular emphasis on emerging companies as they seek to build an infrastructure that allows for increased exports.


There was an interesting study released in Nature on efforts to use vaccines to fight cancer. There's a good overview of the study here.

06.17.11 | By Deborah Oswalt

I am pleased to announce that the Virginia Health Care Foundation (VHCF) presented PhRMA with our prestigious You "Rx"ceptional Award for its work with The Pharmacy Connection at our annual "Heroes in Health Care" ceremony on Tuesday, June 14. PhRMA and VHCF have collaborated over the last decade to provide $1 billion worth of free medicine to uninsured Virginians through The Pharmacy Connection.

06.17.11 | By Ken Thorpe

Throughout the world, chronic non-communicable diseases exert a tremendous economic and social burden. The recent World Health Organization Status Report on Non-communicable Diseases (NCDs) estimates that 63% or 36 million of the 57 million deaths that occurred globally in 2008 were attributable to NCDs , primarily cardiovascular diseases, cancers, diabetes and chronic lung diseases.

06.16.11 | By Kate Connors

Each year, Ernst & Young publishes a report about the global biotechnology sector. In this year's report, which they recently released, they comment about the notable fact that it has been 25 years since they began the report - how far a once-nascent field has evolved in that short amount of time!

It's a hefty read, but they included a really worthwhile two-page chart that details the state of the sector.

06.16.11 | By Kate Connors
In recent months, there has been a good deal of discussion about R&D productivity, with references, for example, to a slight decline in the average number of new medicines approved by the FDA in recent years. This, of course, is at a time when we continue to see record investment in R&D, with America's biopharmaceutical research companies last year investing $67.4 billion in the discovery and development of new medicines.
06.15.11 | By Kate Connors

06.14.11 | By Kate Connors

An op-ed in the Cleveland Plain Dealer by William Burga, a former president of the Ohio AFL-CIO, is a good reminder that support for patent reform - which I've written about in the past - is important not just to biopharmaceutical research companies, but to all sectors that are stimulated by the patent system.

06.13.11 | By Kate Connors

Summer is finally upon us, and though at times it almost seems too steamy to venture outside, it serves as a good reminder about the importance of taking care of your skin.

06.10.11 | By Christian Clymer

06.10.11 | By Kate Connors

Yesterday, PhRMA President and CEO John J. Castellani spoke at the Personalized Medicine Coalition's 7th annual State of Personalized Medicine Luncheon. He spoke about the many challenges confronting the biopharmaceutical sector as it increasingly turns its attention to personalized medicine, but also about the promise that the field offers.

06.09.11 | By Kate Connors

The Association of Nurses in AIDS Care was founded in 1987 with a mission of promoting the individual and collective professional development of nurses involved in the delivery of healthcare to patients with HIV/AIDS. ANAC is a member-driven, chapter-based organization of over 2,500 nurses united to advocate for their HIV patients and advance HIV/AIDS research and standards of HIV care. In its goals is the abiding commitment to the prevention of further HIV infection.

06.09.11 | By Kate Connors

Ezra Klein's column in yesterday's Washington Post on the Medicare prescription drug benefit discusses why costs in Part D have come in beneath expectations. He makes some fair points. But Ezra overlooks the program's unique design that is helping to keep costs far below initial projections and coverage affordable for beneficiaries.